Efficacy and Safety of Prophylactic Tocilizumab in Patients with Multiple Myeloma Receiving Bispecific Antibodies: A Systematic Review and Meta-Analysis
{{output}}
Background: Cytokine release syndrome (CRS) remains a major toxicity associated with bispecific antibody (BsAb) therapy in relapsed/refractory multiple myeloma (RRMM). Prophylactic IL-6 receptor blockade with tocilizumab has emer... ...
